Author(s): No authors listed
Abstract Share this page
Abstract In a phase II trial, combining the granulocyte-macrophage colony-stimulating factor sargramostin and the CTLA-4 inhibitor ipilimumab prolonged survival and caused fewer serious side effects in patients with metastatic melanoma compared with ipilimumab alone.
This article was published in Cancer Discov
and referenced in Journal of Cancer Science & Therapy